125 related articles for article (PubMed ID: 37179150)
1. Methylation status of various gene loci in localized prostate cancer: Novel biomarkers for diagnostics and biochemical recurrence.
Eismann L; von Walter P; Jung A; Chaloupka M; Rodler S; Westhofen T; Buchner A; Stief CG; Stadler T; Schlenker B
Urol Oncol; 2023 Jul; 41(7):325.e1-325.e8. PubMed ID: 37179150
[TBL] [Abstract][Full Text] [Related]
2. A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy.
Angulo JC; Lopez JI; Dorado JF; Sanchez-Chapado M; Colas B; Ropero S
Urol Int; 2016; 97(1):16-25. PubMed ID: 27220660
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
Horning AM; Awe JA; Wang CM; Liu J; Lai Z; Wang VY; Jadhav RR; Louie AD; Lin CL; Kroczak T; Chen Y; Jin VX; Abboud-Werner SL; Leach RJ; Hernandez J; Thompson IM; Saranchuk J; Drachenberg D; Chen CL; Mai S; Huang TH
Prostate; 2015 Nov; 75(15):1790-801. PubMed ID: 26332453
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
5. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer.
Ellinger J; Bastian PJ; Jurgan T; Biermann K; Kahl P; Heukamp LC; Wernert N; Müller SC; von Ruecker A
Urology; 2008 Jan; 71(1):161-7. PubMed ID: 18242387
[TBL] [Abstract][Full Text] [Related]
6. Impact of glutathione-S-transferases (GST) polymorphisms and hypermethylation of relevant genes on risk of prostate cancer biochemical recurrence: a meta-analysis.
Chen R; Ren S; Meng T; Aguilar J; Sun Y
PLoS One; 2013; 8(9):e74775. PubMed ID: 24086370
[TBL] [Abstract][Full Text] [Related]
7.
Holmes EE; Goltz D; Sailer V; Jung M; Meller S; Uhl B; Dietrich J; Röhler M; Ellinger J; Kristiansen G; Dietrich D
Clin Epigenetics; 2016; 8():104. PubMed ID: 27708722
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies.
Trock BJ; Brotzman MJ; Mangold LA; Bigley JW; Epstein JI; McLeod D; Klein EA; Jones JS; Wang S; McAskill T; Mehrotra J; Raghavan B; Partin AW
BJU Int; 2012 Jul; 110(1):56-62. PubMed ID: 22077694
[TBL] [Abstract][Full Text] [Related]
9. GSTP1 CpG island hypermethylation for DNA-based detection of occult tumor cells in surgical margins after radical prostatectomy.
Jentzmik F; Krause H; Reichelt U; Schrader AJ; Schrader M; Baumunk D; Cash H; Miller K; Schostak M
World J Urol; 2012 Aug; 30(4):541-6. PubMed ID: 21947551
[TBL] [Abstract][Full Text] [Related]
10. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.
Bastian PJ; Ellinger J; Heukamp LC; Kahl P; Müller SC; von Rücker A
Eur Urol; 2007 Mar; 51(3):665-74; discussion 674. PubMed ID: 16956712
[TBL] [Abstract][Full Text] [Related]
12. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
Ellinger J; Haan K; Heukamp LC; Kahl P; Büttner R; Müller SC; von Ruecker A; Bastian PJ
Prostate; 2008 Jan; 68(1):42-9. PubMed ID: 18004747
[TBL] [Abstract][Full Text] [Related]
13. Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels.
Haldrup C; Lynnerup AS; Storebjerg TM; Vang S; Wild P; Visakorpi T; Arsov C; Schulz WA; Lindberg J; Grönberg H; Egevad L; Borre M; Ørntoft TF; Høyer S; Sørensen KD
Mol Oncol; 2016 Jun; 10(6):825-37. PubMed ID: 26905753
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
15. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.
Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G
J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865
[TBL] [Abstract][Full Text] [Related]
16. A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.
Castelo-Branco P; Leão R; Lipman T; Campbell B; Lee D; Price A; Zhang C; Heidari A; Stephens D; Boerno S; Coelho H; Gomes A; Domingos C; Apolonio JD; Schäfer G; Bristow RG; Schweiger MR; Hamilton R; Zlotta A; Figueiredo A; Klocker H; Sültmann H; Tabori U
Oncotarget; 2016 Sep; 7(36):57726-57736. PubMed ID: 27437772
[TBL] [Abstract][Full Text] [Related]
17. The investigation of GSTP1, APC and RASSF1 gene promoter hypermethylation in urine DNA of prostate-diseased patients.
Haluskova J; Lachvac L; Nagy V
Bratisl Lek Listy; 2015; 116(2):79-82. PubMed ID: 25665470
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy.
Paziewska A; Dabrowska M; Goryca K; Antoniewicz A; Dobruch J; Mikula M; Jarosz D; Zapala L; Borowka A; Ostrowski J
Br J Cancer; 2014 Aug; 111(4):781-9. PubMed ID: 24937670
[TBL] [Abstract][Full Text] [Related]
19. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
20. Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy.
Wang L; Xie PG; Lin YL; Ma JG; Li WP
Med Sci Monit; 2014 Aug; 20():1363-8. PubMed ID: 25086586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
